Format
Sort by
Items per page

Send to

Choose Destination

Best matches for SOMATROPIN/PD:

Growth hormone therapy with norditropin ( somatropin ) in growth hormone deficiency. Pawlikowska-Haddal A et al. Expert Opin Biol Ther. (2013)

Somatropin treatment of spinal muscular atrophy: a placebo-controlled, double-blind crossover pilot study. Kirschner J et al. Neuromuscul Disord. (2014)

Somatropin: increased mortality? et al. Prescrire Int. (2011)

Search results

Items: 1 to 20 of 2985

1.

Medical Treatments for Acromegaly: A Systematic Review and Network Meta-Analysis.

Leonart LP, Ferreira VL, Tonin FS, Fernandez-Llimos F, Pontarolo R.

Value Health. 2018 Jul;21(7):874-880. doi: 10.1016/j.jval.2017.12.014. Epub 2018 Feb 8. Review.

PMID:
30005760
2.

Long-acting FC-fusion rhGH (GX-H9) shows potential for up to twice-monthly administration in GH-deficient adults.

Ku CR, Brue T, Schilbach K, Ignatenko S, Magony S, Chung YS, Kim BJ, Hur KY, Kang HC, Kim JH, Kim MS, Kowalska A, Bolanowski M, Ruchala M, Damjanovic S, Payer J, Choi YJ, Heo SJ, Kim TK, Heo M, Lee J, Lee EJ.

Eur J Endocrinol. 2018 Sep;179(3):169-179. doi: 10.1530/EJE-18-0185. Epub 2018 Jul 4.

PMID:
29973375
3.

The Use and Abuse of Human Growth Hormone in Sports.

Siebert DM, Rao AL.

Sports Health. 2018 Sep/Oct;10(5):419-426. doi: 10.1177/1941738118782688. Epub 2018 Jun 22. Review.

PMID:
29932857
4.

Safety and convenience of once-weekly somapacitan in adult GH deficiency: a 26-week randomized, controlled trial.

Johannsson G, Feldt-Rasmussen U, Håkonsson IH, Biering H, Rodien P, Tahara S, Toogood A, Rasmussen MH; REAL 2 Study Group.

Eur J Endocrinol. 2018 May;178(5):491-499. doi: 10.1530/EJE-17-1073. Epub 2018 Mar 2.

5.

Design of the Growth hormone deficiency and Efficacy of Treatment (GET) score and non-interventional proof of concept study.

Kann PH, Bergmann S, Bidlingmaier M, Dimopoulou C, Pedersen BT, Stalla GK, Weber MM, Meckes-Ferber S.

BMC Endocr Disord. 2018 Feb 13;18(1):10. doi: 10.1186/s12902-018-0237-3.

6.

Increasing frequency of combination medical therapy in the treatment of acromegaly with the GH receptor antagonist pegvisomant.

Strasburger CJ, Mattsson A, Wilton P, Aydin F, Hey-Hadavi J, Biller BMK.

Eur J Endocrinol. 2018 Apr;178(4):321-329. doi: 10.1530/EJE-17-0996. Epub 2018 Jan 25.

7.

The effects of growth hormone therapy on the somatic development of a group of Polish children with Silver-Russell syndrome.

Sienko M, Petriczko E, Zajaczek S, Zygmunt-Gorska A, Starzyk J, Korpysz A, Petriczko J, Walczak A, Walczak M.

Neuro Endocrinol Lett. 2017 Dec;38(6):415-421.

PMID:
29298282
8.

Challenges and future for the delivery of growth hormone therapy.

Caicedo A, Rosenfeld R.

Growth Horm IGF Res. 2018 Feb;38:39-43. doi: 10.1016/j.ghir.2017.12.008. Epub 2017 Dec 17. Review.

PMID:
29289483
9.

Chronic limb-threatening ischemia could benefit from growth hormone therapy for wound healing and limb salvage.

Caicedo D, Devesa P, Arce VM, Requena J, Devesa J.

Ther Adv Cardiovasc Dis. 2018 Feb;12(2):53-72. doi: 10.1177/1753944717745494. Epub 2017 Dec 22. Review.

10.

New Neoplasm During GH Replacement in Adults With Pituitary Deficiency Following Malignancy: A KIMS Analysis.

Krzyzanowska-Mittermayer K, Mattsson AF, Maiter D, Feldt-Rasmussen U, Camacho-Hübner C, Luger A, Abs R.

J Clin Endocrinol Metab. 2018 Feb 1;103(2):523-531. doi: 10.1210/jc.2017-01899.

PMID:
29228199
11.

Adherence to growth hormone therapy in children and its potential barriers.

Mohseni S, Heydari Z, Qorbani M, Radfar M.

J Pediatr Endocrinol Metab. 2018 Jan 26;31(1):13-20. doi: 10.1515/jpem-2017-0157.

PMID:
29216008
12.

Allergic and non-allergic skin reactions associated with growth hormone therapy: elucidation of causative agents.

Mehta S, Oza V, Potashner R, Zamora P, Raisingani M, Shah B.

J Pediatr Endocrinol Metab. 2018 Jan 26;31(1):5-11. doi: 10.1515/jpem-2017-0309. Review.

PMID:
29197220
13.

Growth response to growth hormone treatment in patients with SHOX deficiency can be predicted by the Cologne prediction model.

Hoyer-Kuhn H, Franklin J, Jones C, Blum WF, Schoenau E.

J Pediatr Endocrinol Metab. 2018 Jan 26;31(1):25-31. doi: 10.1515/jpem-2017-0282.

PMID:
29197219
14.

Pharmacovigilance of Biologics in a Multisource Environment.

Sagi S, Cohen HP, Woollett GR.

J Manag Care Spec Pharm. 2017 Dec;23(12):1249-1254. doi: 10.18553/jmcp.2017.23.12.1249.

15.

Efficacy and Safety of Switching to Pasireotide in Patients With Acromegaly Controlled With Pegvisomant and First-Generation Somatostatin Analogues (PAPE Study).

Muhammad A, van der Lely AJ, Delhanty PJD, Dallenga AHG, Haitsma IK, Janssen JAMJL, Neggers SJCMM.

J Clin Endocrinol Metab. 2018 Feb 1;103(2):586-595. doi: 10.1210/jc.2017-02017.

PMID:
29155991
16.

Reversible brain lesion following growth hormone replacement therapy in an adolescent.

Hadjipanayis A, Efstathiou E, Theophilou L, Chrousos G.

BMJ Case Rep. 2017 Nov 14;2017. pii: bcr-2017-221885. doi: 10.1136/bcr-2017-221885.

PMID:
29141928
17.

[Effect of recombinant human growth hormone therapy on metabolic parameters in patients with craniopharyngioma].

Mao JF, Wang X, Xiong SY, Zheng JJ, Yu BQ, Nie M, Wu XY, Qi ST.

Zhonghua Yi Xue Za Zhi. 2017 Nov 14;97(42):3286-3290. doi: 10.3760/cma.j.issn.0376-2491.2017.42.003. Chinese.

PMID:
29141371
18.

Decorin, a growth hormone-regulated protein in humans.

Bahl N, Stone G, McLean M, Ho KKY, Birzniece V.

Eur J Endocrinol. 2018 Feb;178(2):147-154. doi: 10.1530/EJE-17-0844. Epub 2017 Nov 14.

PMID:
29138241
19.

Efficacy and safety of two doses of Norditropin® (somatropin) in short stature due to Noonan syndrome: a 2-year randomized, double-blind, multicenter trial in Japanese patients.

Ozono K, Ogata T, Horikawa R, Matsubara Y, Ogawa Y, Nishijima K, Yokoya S.

Endocr J. 2018 Feb 26;65(2):159-174. doi: 10.1507/endocrj.EJ17-0313. Epub 2017 Nov 7.

20.

Cardiovascular risk factors and carotid intima media thickness in young adults born small for gestational age after cessation of growth hormone treatment: a 5-year longitudinal study.

van der Steen M, Kerkhof GF, Smeets CCJ, Hokken-Koelega ACS.

Lancet Diabetes Endocrinol. 2017 Dec;5(12):975-985. doi: 10.1016/S2213-8587(17)30311-X. Epub 2017 Nov 1.

PMID:
29102566

Supplemental Content

Loading ...
Support Center